The Toronto-Dominion Bank ( TD Quick Quote TD - Free Report) is slated to announce first-quarter fiscal 2021 (ended Jan 31) results on Feb 25, before the opening bell. Both earnings and revenues are expected to have witnessed a decline on a year-over-year basis. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Higher net interest income primarily supported the results. Toronto-Dominion has a decent earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on another occasion, with an average surprise of 13.8%.
The Zacks Consensus Estimate for earnings has moved nearly 1% north over the past 30 days to $1.16 per share, which indicates a decline of 7.9% from the prior-year reported number.
The consensus estimate for sales is pegged at $7.98 billion, suggesting a dip of 1% from the year-ago quarter. Before we take a look at what our quantitative model predicts, let’s check out the factors that are expected to have impacted Toronto-Dominion’s fiscal first-quarter performance. Factors at Play Net Interest Income (NII): Overall demand for loans was muted in the November-January quarter, mainly due to declining commercial lending. This, along with a low interest rate environment, is expected to have hampered the company’s NII growth. Investment Banking Revenues: As economic and business activities have started to gradually resume, deal making continued to gain pace in the to-be-reported quarter. Thus, with an increase in global M&A volumes, Toronto-Dominion’s advisory fees are likely to have been positively impacted. IPO activities were high in the to-be-reported quarter. Further, as companies continued to build liquidity to tide over the pandemic-induced crisis, there was a rise in follow-up equity issuances. Moreover, bond issuance volumes were strong as companies took this as an opportunity to bolster their balance sheets. Hence, growth in Toronto-Dominion’s underwriting fees is likely to have been decent in the fiscal first quarter. Trading Revenues: Driven by persistent coronavirus-induced uncertainty, equity markets witnessed a significant rise in volatility and higher client activity in the fiscal first quarter. Moreover, fixed income markets’ performance remained strong. Hence, its equity and fixed income markets’ revenues are expected to have improved in the to-be-reported quarter. Provisions: Toronto-Dominion, having already built significant reserves owing to deterioration in the macro-economic backdrop in fiscal 2020, is less likely to have recorded a substantial increase in provision for loan losses in the fiscal first quarter. Further, unlike its U.S. peers that have already begun releasing reserves, the company is less likely to do so this time. What Our Model Predicts
The chances of Toronto-Dominion beating the Zacks Consensus Estimate this time are high. This is because it has the right combination of the two key ingredients — a positive
Earnings ESP and a Zacks Rank #3 (Hold) or better. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP for Toronto-Dominion is +2.45%. Zacks Rank: The company currently has a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here Performance & Earnings Release Dates of Other Foreign Banks Barclays ( BCS Quick Quote BCS - Free Report) reported fourth-quarter 2020 net income attributable to ordinary equity holders of £220 million ($290.5 million), down 67.7% from the prior-year period. Royal Bank of Canada ( RY Quick Quote RY - Free Report) and Canadian Imperial Bank of Commerce ( CM Quick Quote CM - Free Report) are scheduled to announce quarterly numbers on Feb 24 and Feb 25, respectively. Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>